Mosebrook Jeffrey 4

What Happened
Jeffrey Mosebrook, SVP, Finance & Principal Accounting Officer at Integra LifeSciences (IART), received a grant of 15,957 restricted stock units (RSUs) on 2026-03-11. To satisfy tax/withholding obligations related to the award, 341 shares were disposed on 2026-03-10 at $9.55 each ($3,257) and 806 shares were disposed on 2026-03-11 at $9.61 each ($7,746), for total withholding of about $11,003. The RSU award is reported as a derivative grant (no cash outlay by Mosebrook).

Key Details

• Transaction dates and amounts:
  • 2026-03-10: 341 shares disposed (tax withholding) at $9.55 — $3,257.
  • 2026-03-11: 806 shares disposed (tax withholding) at $9.61 — $7,746.
  • 2026-03-11: 15,957 RSUs granted (derivative award) at $0.00.
• Shares owned after the transactions: not disclosed in this filing.
• Footnote: RSU vesting schedule — 33% on each of the first and second anniversaries and 34% on the third anniversary of the 3/11/2026 grant date.
• Filing timeliness: Form 4 was filed on 2026-03-12 for transactions on 3/10–3/11; no late filing is indicated.

Context
The award (A) is a standard RSU grant that vests over three years. The disposals coded F represent share withholding to cover tax liabilities tied to the award — a routine administrative action, not an open-market sale that signals a personal liquidity decision. For retail investors, RSU grants indicate management compensation alignment with shareholders, while withholding disposals are common and typically not a directional signal about company prospects.